MediWound (NASDAQ:MDWD) Stock Passes Below 200-Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $17.86 and traded as low as $16.73. MediWound shares last traded at $16.96, with a volume of 82,317 shares changing hands.

Analyst Ratings Changes

MDWD has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $36.00 price target (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Wall Street Zen downgraded MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $31.67.

MediWound Price Performance

The company has a market capitalization of $217.26 million, a PE ratio of -8.08 and a beta of 0.13. The company’s fifty day moving average is $17.38 and its 200-day moving average is $17.86.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. The company had revenue of $1.87 million during the quarter, compared to analyst estimates of $2.09 million. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. Equities research analysts forecast that MediWound Ltd. will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of institutional investors have recently added to or reduced their stakes in MDWD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 999 shares during the last quarter. Rhumbline Advisers lifted its position in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 481 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of MediWound in the 2nd quarter worth approximately $317,000. Finally, Menora Mivtachim Holdings LTD. purchased a new position in shares of MediWound in the 2nd quarter worth approximately $339,000. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.